deltatrials
Completed PHASE3 NCT00000513

Trial of Antihypertensive Intervention Management

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Cardiovascular Diseases Heart Diseases Hypertension Vascular Diseases
Interventions atenolol chlorthalidone diet, reducing diet, sodium-restricted
Updated 5 times since 2017 Last updated: Nov 25, 2013 Started: Apr 30, 1984 Completion: Nov 30, 1994

This PHASE3 trial investigates Cardiovascular Diseases and Heart Diseases and is currently completed. National Heart, Lung, and Blood Institute (NHLBI) leads this study, which shows 5 recorded versions since 1984 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Apr 1984

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: National Heart, Lung, and Blood Institute (NHLBI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.